Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| MIRA Pharmaceuticals Inc. | Ketamir-2 (Topical) | Neuropathic pain and chemo-induced depression, as well as neuropathic pain and PTSD | Phase 2a | Ongoing | Topical | Psychiatric |
| Miromatrix Medical Inc. | miroliverELAP | Acute Liver Failure | Phase 2 | Trial Planned | oral | N/A |
| Mirum Pharmaceuticals Inc. | Brelovitug - (AZURE) | chronic hepatitis delta virus (HDV) | Phase 3 | Ongoing | Intravenous | Antiviral |
| Mirum Pharmaceuticals Inc. | Volixibat - (VISTAS) | Primary sclerosing cholangitis | Phase 2b | Data Released | Oral | Gastroenterology |
| Mirum Pharmaceuticals Inc. | Volixibat - (VANTAGE) | Pruritus associated with primary biliary cholangitis | Phase 2b | Data Released | Oral | Gastroenterology |
| Mirum Pharmaceuticals Inc. | Maralixibat - (EMBARK) | Biliary atresia | Phase 2b | Trial Discontinued | Oral | Gastroenterology |
| Mirum Pharmaceuticals Inc. | Volixibat - (OHANA) | Intrahepatic cholestasis of pregnancy | Phase 2b | Trial Discontinued | Oral | Women's Health |
| Mirum Pharmaceuticals Inc. | MRM-3379 (ENT-3379) - (BLOOM) | Fragile X Syndrome (FXS) | Phase 2 | Enrollment Initiation | Oral | Genetic Disorder |
